Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January.
Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use.
Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity.
Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy, VIT is the only treatment that can prevent systemic inflammatory reactions to bee or wasp stings and significantly improve quality of life, even for people with less severe allergic reactions.2
“Entomon’s activities complement Stallergenes Greer’s portfolio and strengthen our control of critical allergen extracts, notably Hymenoptera venoms used in allergen immunotherapy” stated Dr. Andreas Amrein, Chairman and CEO of Stallergenes Greer. “This acquisition secures long-term access to high-quality venom extracts in a market constrained by limited global capacity. It also builds on our existing partnerships and supports a diversified model for venom immunotherapy components. By reinforcing supply chain diversification and building on our well-established position in venom immunotherapy with Albey®, we strengthen our ability to support patients and healthcare professionals worldwide and deliver on our long-term commitment to high-standard, reliable allergy care. We are delighted to welcome Entomon to the Stallergenes Greer Group.”
“Becoming part of Stallergenes Greer marks a transformative moment for Entomon. It is a testament to our expertise in the extraction of pure Hymenoptera venom and our ability to deliver high-quality raw materials which are essential for life-saving allergen immunotherapies. We are excited to embark on this new chapter,” declared Dr. Elisabetta Francescato, CEO and founder of Entomon s.r.l.
About hymenoptera venom allergies
Stinging-insect venom sensitisation is common in the general population (between 9.3% and 28.7%), and more than half of the population will be stung by an insect at least once in their lifetime depending on the living environment and type of activity.34
Venom allergy is an IgE-mediated hypersensitivity reaction triggered by stings from insects such as bees, wasps, hornets, or other Hymenoptera species. While local reactions are common and usually mild, venom-allergic individuals can experience systemic responses ranging from widespread hives to severe anaphylaxis. Hymenoptera venom allergy is the primary cause of anaphylaxis in adults in Europe, being responsible for 48.2% of cases and 20.2% in children worldwide5. Based on national mortality surveillance, fatal anaphylaxis due to Hymenoptera stings accounts for approximately 72 deaths per year in the United States6, while European data indicate a comparable burden of about 73 deaths annually across 32 countries7.
Diagnosis relies on a combination of clinical history, skin testing, and specific IgE measurement to identify the responsible insect. Venom immunotherapy is the only treatment proven to modify the natural course of venom allergy. It provides long-term protection by inducing immune tolerance8, markedly reducing the risk of systemic reactions to future stings and improving patients’ quality of life.
Because Hymenoptera venoms differ by species, the availability and quality of venom extracts are essential to enable accurate diagnosis and effective immunotherapy, ensuring patients receive targeted and reliable treatment.
About Albey® Venoms
Albey® Venoms are standardised purified extracts derived from hymenoptera species, including honeybee (Apis mellifera), yellow jacket (Vespula spp.), and paper wasp (Polistes spp.). These extracts are specifically designed for Venom Immunotherapy (VIT), the only proven treatment to prevent severe systemic allergic reactions.
Albey® holds marketing authorisations in France, Italy, Australia and New Zealand. It is also available in Italy under ope legis status.
About Entomon
Based in Florence (Italy), Entomon s.r.l. is a privately held company established by leading biologists and naturalists with deep expertise in the study of insects and their impact on human health and activity. The company specialises in the extraction of pure insect venom extracts for diagnostic reagents and venom immunotherapy for individuals with insect sting allergies. Entomon is the sole producer in Europe of insect of pure, certified Hymenoptera venom extracts. For more information, please visit: www.entomon.it
About Stallergenes Greer
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, please visit www.stallergenesgreer.com.
1 Hymenoptera (bee and wasp) Stevens et al. Recent insights into the mechanisms of anaphylaxis. Curr Opin Immunol. 2023 Apr;81
2 EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy (Allergy. 2018 Apr;73(4):744-764)
3 Bilò, M. B., Pravettoni, V., Bignardi, D., Bonadonna, P., Mauro, M., Novembre, E., ... & Pastorello, E. A. (2019). Hymenoptera venom allergy: management of children and adults in clinical practice. Journal of investigational allergology & clinical immunology, 29(3), 180-205.
4 Golden, D. B., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., ... & Wallace, D. (2017). Stinging insect hypersensitivity: a practice parameter update 2016. Annals of Allergy, Asthma & Immunology, 118(1), 28-5
5 Rueff et al., (2023) Diagnosis and treatment of Hymenoptera venom allergy
6 QuickStats: Number of Deaths from Hornet, Wasp, and Bee Stings Among Males and Females — National Vital Statistics System, United States, 2011–2021. MMWR Morb Mortal Wkly Rep 2023;72:756.
7 Feás, X.; Vidal, C.; Remesar, S. What We Know about Sting-Related Deaths? Human Fatalities Caused by Hornet, Wasp and Bee Stings in Europe (1994–2016). Biology 2022, 11, 282. https://doi.org/10.3390/biology11020282
8 Golden et al. J Allergy Clin Immunol. 2011 Apr ;127(4):852-4.e1-23
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107561851/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estée Lauder Announces Actress Daisy Edgar-Jones as Newest Global Brand Ambassador8.1.2026 14:00:00 CET | Press release
Estée Lauder today announced that it has signed acclaimed British actress, Daisy Edgar-Jones, as its newest Global Brand Ambassador. Daisy will represent Estée Lauder skin care, makeup, and fragrance, with her first campaign debuting on February 2nd across print, digital and in-store. She joins Estée Lauder’s current roster of global talent including Ana de Armas, Bianca Brandolini, Carolyn Murphy, Imaan Hammam, IU, Karlie Kloss, Paulina Porizkova and Yang Mi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108459289/en/ Daisy Edgar-Jones for Estée Lauder “As an actress, I love how makeup can tell a story of who we are. I have always admired how Estée Lauder celebrates confidence and individuality in women. The legacy, elegance, and strength of the brand is so inspiring,” said Daisy Edgar-Jones. “It feels surreal to be part of the Estée Lauder family – and it truly feels like a family.” “Daisy is very much the breakout sta
Kinaxis Appoints Razat Gaurav as New CEO8.1.2026 14:00:00 CET | Press release
With over two decades of supply chain experience and a proven record of driving global growth Razat Gaurav is uniquely positioned to lead Kinaxis in its next phase of AI-driven innovation. Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/ Razat Gaurav, Kinaxis CEO “After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forw
Liberty Latin America Expands Exclusive International Voice Managed Services Partnership with BTS to 22 Additional Caribbean Markets8.1.2026 13:30:00 CET | Press release
BTS, the leading provider, technology enabler, and trusted partner to CommTech players worldwide, has been appointed by Liberty Latin America (LLA) as the exclusive provider of International Voice Managed Services for 22 additional Caribbean markets. This expansion builds on the successful 2023 partnership, in which BTS was selected as the exclusive international voice provider for Costa Rica, Panama, Puerto Rico, and the U.S. Virgin Islands. With this agreement, BTS will now support International Long Distance (ILD) services across a total of 26 LLA markets. Effective January 1, 2026, BTS began handling ILD voice services for the newly added Caribbean markets, enabling greater service consistency, enhanced quality, and improved operational efficiency across LLA’s regional footprint. The 22 new markets incorporated under the expanded partnership include: Anguilla, Antigua, Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman, Curaçao, Dominica, Grenada, Jamaica, Montserrat, Saba,
Det-Tronics Acquires Optronics8.1.2026 13:28:00 CET | Press release
Optronics is a global leader in optical gas detection products and solutions for high-hazard, mission-critical applications Det-Tronics, a global leader in fire and gas safety systems, has acquired Optronics, a Norway-based company that specializes in optical gas detection technologies. Det-Tronics is part of Spectrum Safety Solutions that is based in Stamford, CT. Optronics, founded in 2018, is a technology leader in high-end optical gas detection products and solutions for energy, marine and industrial applications. Optronics has a strong record of innovation, bringing leading products and expert solutions to market for its customers. (www.optronics-technology.com) “Det-Tronics’ strategy is built on growth, innovation and quality. Optronics and Det-Tronics are a perfect fit to grow our businesses, drive new innovations and lead the market with high quality and reliable products and solutions,” noted Johannes Mario Kahlert, President of Det-Tronics. “We are very excited for the path a
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 13:00:00 CET | Press release
V-212 was well tolerated and demonstrated an excellent safety profileRobust IgG responses were observed to all three antigens in the vaccineResults support further development of V-212 independently and in combination with approved pneumococcal conjugate vaccines (PCVs) Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom